Deutsche Bank Initiating Coverage on Anthera Pharmaceuticals

Deutsche Bank is out with a research report on Anthera Pharmaceuticals

and is initiating coverage with a Buy rating and a $14 price target on shares. In a note to clients, Deutsche Bank writes, "Anthera is a small-cap biotech company w/ 2 key pipeline candidates: 1) varespladib for acute coronary syndrome (

) & 2) blisibimod (B-mod) for systemic lupus erythematosus (

). Both are lucrative opportunities. Street does not assign value to varespladib ph 3 VISTA-16 trial hitting due to high-risk nature. In our opinion, this has opened an investment opportunity. We calculate risk/reward to be very favorable at 30% down & 5x up. We apply a 30% probability of success for varespladib." Shares of ANTH closed at $6.35 yesterday.